Little Green Pharma Ltd announced on Monday it had entered into a medicinal cannabis distribution agreement with Sana Life Sciences. Under the Agreement, the parties grant each other mutual exclusivity across the UK and Crown Dependencies for the supply or distribution of LGP 10:10 Classic Oil and other oils with the same or similar ratios. But this is subject to Sana meeting certain minimum exclusivity purchase thresholds per annum. LGP says the agreement represents an annual revenue opportunity of A$1.44m post-ramp up for just the exclusive oil product. The agreement also covers a non-exclusive supply of LGP’s Classic Oils and Desert Flame flower medicines, along with an LGP-branded flower product that is currently in development. “… the Agreement represents a key step in LGP’s twin strategy of selling its own LGP-branded sales into the UK and EU while developing and supplying client-specific white-label strains for clients across Europe,” stated the company. In other recent news from Little Green Pharma, the firm recently released its activities report for the quarter ending March 31, 2022 indicating unaudited revenue of $3.2 million and cash receipts of $3.0 million.
Cannabis Law Report, 05/05/2022 01:38:00